Integrated Advancements in Neuroplasticity, Psychedelic Therapeutics, and AI-Driven Innovations for Precision Medicine.
ACS medicinal chemistry letters April 10, 2025 DOI: 10.1021/acsmedchemlett.5c00112 via PubMed
Summary
AI-generated from the abstractAdvancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms are opening new possibilities in precision medicine. These innovations target neurological and psychiatric disorders, chronic pain, and computational accessibility through receptor modulation, targeted delivery, and simplified AI integration. They promise transformative solutions for patient care and technological development.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Key finding | Innovations in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI platforms address challenges in neurological and psychiatric disorders, chronic pain, and computational accessibility. |
Abstract
Recent advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms mark a new frontier in precision medicine. These innovations address critical challenges in neurological and psychiatric disorders, chronic pain management, and computational accessibility. By harnessing the principles of receptor modulation, targeted delivery systems, and simplified AI integration, these breakthroughs promise transformative solutions for patient care and technological development.